Sermorelin: growth-hormone secretagogue research
Evaluating sermorelin claims without treating a GH-releasing peptide narrative as proof of benefit.
Educational information only — not medical advice. This page does not diagnose conditions, recommend treatment, or replace care from a qualified clinician. The Peptide Center uses an evidence-first editorial process: regulatory sources, trial registries, and peer-reviewed research take priority; uncertainty is stated rather than filled with promises.
Sermorelin is a growth-hormone-releasing hormone (GHRH) analogue studied in endocrine research. Historically, certain sermorelin products had FDA-approved diagnostic uses; many products discussed online today are not FDA-approved medicines and should not be described as such without verification.
References
- Therapeutic peptides: recent advances in discovery, synthesis, and clinical applications. Signal Transduction and Targeted Therapy, 2022
- ClinicalTrials.gov: Learn about studies
- FDA: The drug development process
Related resources
Continue with curated, same-topic resources from the published library. These links are educational references, not treatment recommendations.
CJC-1295 No DAC
A framework for evaluating performance claims without treating a biological mechanism as proof of benefit.
Open resourcePeptide briefCJC-1295 No DAC / Ipamorelin
A framework for evaluating performance claims without treating a biological mechanism as proof of benefit.
Open resourcePeptide briefCJC-1295 With DAC
A framework for evaluating performance claims without treating a biological mechanism as proof of benefit.
Open resourcePeptide briefFollistatin 344
Why a compelling cell or animal result is the beginning of a question, not the end of it.
Open resourcePeptide briefGHRP-2
How to evaluate claims involving GHRP compounds, biomarkers, body composition, and recovery.
Open resourcePeptide briefGHRP-6
How to evaluate claims involving GHRP compounds, biomarkers, body composition, and recovery.
Open resourceArticleWhy a biological mechanism is not a treatment promise
A practical explanation of why plausible pathways still need meaningful human-outcome evidence.
Open resource